List of Hetlioz Lq drug patents
Hetlioz Lq is owned by Vanda Pharms Inc.
Hetlioz Lq contains Tasimelteon.
Hetlioz Lq has a total of 16 drug patents out of which 1 drug patent has expired.
Expired drug patents of Hetlioz Lq are:
- US5856529
Hetlioz Lq was authorised for market use on 01 December, 2020.
Hetlioz Lq is available in suspension;oral dosage forms.
Hetlioz Lq can be used as treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin, treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history, treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon.
The generics of Hetlioz Lq are possible to be released after 11 December, 2040.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(3 months ago) | |
| US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(11 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(11 years from now) | |
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(9 years from now) | |
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(11 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(11 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(11 years from now) | |
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(12 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(12 years from now) | |
| US11202770 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Dec, 2040
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION;ORAL
HETLIOZ LQ family patents
65
United States
22
Japan
20
Australia
19
Korea, Republic of
11
Canada
11
European Union
9
China
8
Mexico
6
Israel
4
Russia
4
Spain
4
New Zealand
4
Chile
3
Colombia
2
Portugal
2
Brazil
2
Croatia
2
India
2
Slovenia
2
Hungary
2
Denmark
1
Hong Kong
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic